BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2016

Jan 21, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2016-01-19

Reporting Person: STAAB THOMAS R II (Senior Vice President and CFO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-19	Common Stock	M	2500	$3.78	Acquired	137416	Direct
2016-01-19	Common Stock	M	12500	$1.42	Acquired	149916	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-19	Emp. Stock Option (Right to Buy)	$3.78	M	2500	Disposed	2021-07-01	Common Stock (2500)	Direct
2016-01-19	Emp. Stock Option (Right to Buy)	$1.42	M	12500	Disposed	2023-01-01	Common Stock (12500)	Direct